Locum Consultant NeurologistNHS

Job summary

Locum Consultant Neurologist with a Special interest in Headache and Facial Pain (12 months) We are seeking an enthusiastic and experienced Consultant Neurologist to join the Headache Service at the National Hospital for Neurology and Neurosurgery (NHNN), Queen Square, on a 12-month locum basis.This 5 PA post offers an opportunity to work within a nationally and internationally recognised specialist service for complex headache and facial pain. You will help maintain continuity of care for existing patients while contributing to the development of specialist services, particularly CGRP monoclonal antibody and Gepant therapies and the urgent assessment and treatment of cluster headache and other trigeminal autonomic cephalalgias.You will work alongside experienced neurologists, specialist nurses, psychologists, neurosurgeons and neuroradiologists in a highly collaborative environment with strong links to research, education and innovation.

Main duties of the job

You will deliver three dedicated headache and facial pain outpatient clinics each week, provide care for inpatients under your responsibility and undertake the associated clinical administration and correspondence.The role has a particular focus on delivering 18-week Referral to Treatment pathways, the CGRP monoclonal antibody and Gepant therapy service, and timely specialist assessment and treatment for patients with cluster headache and other trigeminal autonomic cephalalgias.You will contribute to multidisciplinary working, including collaboration with neurosurgery and neuroradiology where required, and participate in the wider clinical and professional activities of the service. The successful candidate will demonstrate strong clinical expertise in complex headache and facial pain disorders, excellent communication skills, the ability to work effectively within an interdisciplinary team, and a commitment to teaching, research and continuous improvement.

Job description

For the full Person Specification and more information regarding the main responsibilities of this role, please refer to the attached Job Description.

The post-holder will be responsible for maintaining continuity of care for patients managed by the preceding consultant while contributing to the development of services, with particular emphasis on CGRP monoclonal antibody and Gepant therapy and services for patients with cluster headache and other trigeminal autonomic cephalalgias.

The role involves evaluating and treating a range of complex headache conditions, including patients who are candidates for CGRP blocking treatment, alongside urgent assessment and treatment initiation for cluster headache patients. The post-holder will work collaboratively with colleagues across the multidisciplinary team and contribute to timely, specialist care within the established 18-week treatment pathway.

The successful candidate will be eligible for full GMC registration with a current licence to practise and will hold, or be within six months of, a CCST in Neurology with appropriate Specialist Register status, or be progressing through the relevant Portfolio Pathway. They will hold MRCP(UK) or an equivalent qualification and have comprehensive knowledge of neurological disorders, with clinical expertise in complex headache and facial pain disorders, including trigeminal autonomic cephalalgias. Candidates should demonstrate the ability to run an effective clinical service, identify appropriate investigations and onward referrals, communicate clearly in written and spoken English, and work effectively within an interdisciplinary or multispecialty team. They should also demonstrate leadership, sound decision-making, a commitment to teaching and continuing professional development, and the ability to work in line with UCLH's values of Safety, Kindness, Teamwork and Improving. Desirable experience includes a PhD, MD or equivalent specialist training, teaching experience, involvement in formal educational programmes, organisational experience, and a proven commitment to high-quality research and publication in peer-reviewed journals.

Come and be a part of the best NHS trust in England to work for, according to our staff*

• UCLH top trust to work at in England - In the most recent NHS staff survey UCLH had the highest percentage of staff who said they would recommend us as a place to work, out of all general acute or acute/community NHS trusts in England for the third year in a row.

UCLH recognises the benefits of flexible working for staff To find out more, visit: Flexible working.

To discover more about what makes UCLH a great place to work, visit: Why Choose UCLH?

About us

University College London Hospitals NHS Foundation Trust (UCLH) is one of the most complex NHS trusts in the UK, serving a large and diverse population. We provide academically led acute and specialist services, to people from the local area, from throughout the United Kingdom and overseas. Our vision is to deliver top-quality patient care, excellent education, and world-class research.

We provide first-class acute and specialist services across eight sites:o University College Hospital (incorporating the Elizabeth Garrett Anderson Wing)o National Hospital for Neurology and Neurosurgeryo Royal National ENT and Eastman Dental Hospitalso University College Hospital Grafton Way Buildingo Royal London Hospital for Integrated Medicineo University College Hospital Macmillan Cancer Centreo The Hospital for Tropical Diseaseso University College Hospital at Westmoreland Street

We are dedicated to the diagnosis and treatment of many complex illnesses. UCLH specialises in women's health and the treatment of cancer, infection, neurological, gastrointestinal and oral disease. It has world class support services including critical care, imaging, nuclear medicine and pathology.

We are committed to sustainability and have pledged to become a carbon net zero health service, embedding sustainable practice throughout UCLH. We have set an ambitious target of net zero for our direct emissions by 2031 and indirect emissions by 2040.